Active ingredients: zanamivir
What it is used for
Treatment: Relenza (zanamivir) is indicated for the treatment of infections due to Influenza A and B viruses in adults and children aged 5 years and older. Treatment should commence as soon as possible but no later than forty-eight hours after the onset of the initial symptoms of infection (see Precautions). Prophylaxis: Vaccination remains the primary method of preventing and controlling influenza. Relenza is indicated for prophylaxis of Influenza A and B in adults and children (5 years and older) to reduce transmission among individuals in households with an infected person. Relenza is indicated for prophylaxis of influenza A and B during community outbreaks only in circumstances where such prophylaxis is justified (such as when vaccine that antigenically matches circulating influenza is not available or there is a pandemic). It is not recommended for routine prophylaxis against influenza infection.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Inhalation
- Store below 30 degrees Celsius
- Lifetime is 10 Years.
Always read the label. If symptoms persist see your healthcare professional.
Circular foil pack, approximately 4cm in diameter, with four regularly distributed blisters, each containing a white to off-white powder.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
Is this medicine subsidised?
This medicine may be subsidised which may make it cheaper. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient zanamivir
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)